ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2026
Impella™-protected PCI in a post-CABG patient with advanced biventricular dysfunction and mitral regurgitation.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with advanced coronary artery disease (CAD), severely reduced left ventricular (LV) ejection fraction, and prior coronary artery bypass grafting (CABG) present with complex revascularization challenges requiring individualized, multidisciplinary decision-making and pre-procedural strategy planning. Protected percutaneous coronary intervention (PCI) using percutaneous temporary mechanical circulatory support, such as the Impella™ microaxial flow pump, may enable complex revascularization in carefully selected patients at high risk of peri-procedural haemodynamic compromise. We describe a male patient with advanced ischaemic cardiomyopathy, severe functional mitral regurgitation, and complex multivessel CAD, including chronic total occlusion (CTO) of the left anterior descending artery, following prior CABG. After Heart Team discussion and in the context of prohibitive surgical risk, a staged strategy was carefully planned pre-procedurally and then pursued with mitral transcatheter edge-to-edge repair, followed by prophylactic Impella-assisted PCI. Under haemodynamic support, retrograde CTO PCI via a patent saphenous vein graft was performed with drug-eluting stent implantation and intravascular ultrasound-confirmed optimization, achieving TIMI 3 flow. The patient remained haemodynamically stable, with an uneventful post-procedural course and no vascular or cardiac complications. This case illustrates how a staged Impella-protected PCI strategy can facilitate revascularization in post-CABG patients with advanced LV dysfunction and be integrated into a timely, planned, and patient-tailored approach accounting for ventricular function, valvular disease, and complex coronary anatomy when surgery is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.